This article is part of a Chronicle. See more from this Chronicle
Rachel Brandenburger, Mark Jones, Oct 15, 2014
In Europe, the question of whether there is, or should be, a role for national interest considerations in the review of corporate acquisitions by foreign purchasers has made headline news several times this year. In the Spring, Pfizer’s proposed bid for AstraZeneca sparked concerns in the United Kingdom about whether the takeover of a U.K.-based company by a U.S.-based one would
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 3.137.175.166
Please verify email or join us to access premium content!